202 related articles for article (PubMed ID: 26586560)
41. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
42. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
43. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
44. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
[TBL] [Abstract][Full Text] [Related]
45. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
46. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Chiang KL; Chang KP; Lee YY; Huang PI; Hsu TR; Chen YW; Chang FC; Wong TT
Childs Nerv Syst; 2010 Aug; 26(8):1035-41. PubMed ID: 20217098
[TBL] [Abstract][Full Text] [Related]
47. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
48. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Lasolle H; Raverot G
Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
[TBL] [Abstract][Full Text] [Related]
51. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
52. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L; Gupta N; Dutta P; Walia R; Vaiphei K; Rai A; Radotra BD; Gupta K; Sreedharanunni S; Ahuja CK; Bhansali A; Tripathi M; Sood R; Dhandapani S
Front Endocrinol (Lausanne); 2021; 12():774686. PubMed ID: 34975752
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
54. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
[TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Sol B; de Filette JMK; Awada G; Raeymaeckers S; Aspeslagh S; Andreescu CE; Neyns B; Velkeniers B
Eur J Endocrinol; 2021 Jan; 184(1):K1-K5. PubMed ID: 33112279
[TBL] [Abstract][Full Text] [Related]
56. Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
[TBL] [Abstract][Full Text] [Related]
57. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
58. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Chamberlain MC
J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
[TBL] [Abstract][Full Text] [Related]
59. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Rudà R; Bosa C; Magistrello M; Franchino F; Pellerino A; Fiano V; Trevisan M; Cassoni P; Soffietti R
Neuro Oncol; 2016 Feb; 18(2):261-8. PubMed ID: 26323606
[TBL] [Abstract][Full Text] [Related]
60. Salvage temozolomide for prior temozolomide responders.
Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
